New Systems Offer Cost-Effective Urinalysis at Any Lab Scale
|
By LabMedica International staff writers Posted on 22 Jul 2019 |

Image: The LAURA automated urine analyzer (Photo courtesy of Erba Mannheim).

Image: The LAURA XL automated urine analyzer (Photo courtesy of Erba Mannheim).
With the growing prevalence of kidney-related diseases, proper screening and detection have become an increasing priority for clinicians. Two newly introduced systems, LAURA and LAURA XL, now aim to fill the need for such reliable, automated, and affordable urinalysis.
LAURA is a semi-automated strip reader using reflectance photometry for objective evaluation of color reactions on diagnostic pads. It offers evaluation of 12 clinically significant parameters: specific gravity, leukocytes, nitrites, pH, protein, glucose, ketones, urobilinogen, bilirubin, blood, microalbumin, and creatinine, as well as calculation of protein/creatinine ratio.
The instrument operates with continuous loading and throughput of 400 tests per hour. Convenient sample identification and data input via barcode reader and LIS connectivity minimize potential data management errors and reflect the need for increased efficiency and safety. The intuitive user interface has been designed to offer a broad range of optimized features such as results flagging and recommendation for additional sediment evaluation or customized reporting options.
Overall, the LAURA reader, with PHAN diagnostic strips and URINORM control urines, provides a complete solution to optimize laboratory workflow. This instrument offers affordable automation for smaller and mid-sized labs, or serves as reliable backup system for fully automated larger labs.
The LAURA XL is a fully automated urine analyzer combining trusted urine strip analysis and digital microscopy. It offers automatic evaluation of 10 chemistry parameters and 16 sediment categories. In addition, users can select from 16 manual and four customizable sediment categories. Concentration of sediment particles is achieved without centrifugation by gravitational sedimentation.
This is a very gentle technique preventing damage of fragile elements and allowing cost-effective measurement by replacing disposable cuvettes with a long-life, washable cuvette module. Due to clear high-resolution imagery, LAURA XL reduces the need for additional evaluation of results by visual microscopy.
The LAURA XL system - a powerful tool for larger labs looking for a high-performance solution to automate their routine urinalysis requirements - is delivered with special adaptors, which enable measurement of low volume samples - minimal volume for analysis of both urine chemistry and sediment is then 0.9 microliters of urine. It operates in three modes: chemistry only (180 tests/hour), sediment only (140 tests/hour), and hybrid (140 tests/hour).
The LAURA and LAURA XL clinical urinalysis systems were developed and are being introduced by Erba Mannheim (Mannheim, Germany), a global IVD company focused on delivering total solutions for clinical diagnostics.
LAURA is a semi-automated strip reader using reflectance photometry for objective evaluation of color reactions on diagnostic pads. It offers evaluation of 12 clinically significant parameters: specific gravity, leukocytes, nitrites, pH, protein, glucose, ketones, urobilinogen, bilirubin, blood, microalbumin, and creatinine, as well as calculation of protein/creatinine ratio.
The instrument operates with continuous loading and throughput of 400 tests per hour. Convenient sample identification and data input via barcode reader and LIS connectivity minimize potential data management errors and reflect the need for increased efficiency and safety. The intuitive user interface has been designed to offer a broad range of optimized features such as results flagging and recommendation for additional sediment evaluation or customized reporting options.
Overall, the LAURA reader, with PHAN diagnostic strips and URINORM control urines, provides a complete solution to optimize laboratory workflow. This instrument offers affordable automation for smaller and mid-sized labs, or serves as reliable backup system for fully automated larger labs.
The LAURA XL is a fully automated urine analyzer combining trusted urine strip analysis and digital microscopy. It offers automatic evaluation of 10 chemistry parameters and 16 sediment categories. In addition, users can select from 16 manual and four customizable sediment categories. Concentration of sediment particles is achieved without centrifugation by gravitational sedimentation.
This is a very gentle technique preventing damage of fragile elements and allowing cost-effective measurement by replacing disposable cuvettes with a long-life, washable cuvette module. Due to clear high-resolution imagery, LAURA XL reduces the need for additional evaluation of results by visual microscopy.
The LAURA XL system - a powerful tool for larger labs looking for a high-performance solution to automate their routine urinalysis requirements - is delivered with special adaptors, which enable measurement of low volume samples - minimal volume for analysis of both urine chemistry and sediment is then 0.9 microliters of urine. It operates in three modes: chemistry only (180 tests/hour), sediment only (140 tests/hour), and hybrid (140 tests/hour).
The LAURA and LAURA XL clinical urinalysis systems were developed and are being introduced by Erba Mannheim (Mannheim, Germany), a global IVD company focused on delivering total solutions for clinical diagnostics.
Latest Technology News
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
- Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
- Online Tool Supports Family Screening for Inherited Cancer Risk
- Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
- New Electronic Pipette Enhances Workflows with Touchscreen Control
- AI Model Outperforms Clinicians in Rare Disease Detection
- AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
- Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
- AI-Powered Biomarker Predicts Liver Cancer Risk
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Channels
Clinical Chemistry
view channel
Blood Metabolite Test Detects Early Cognitive Decline
Timely identification of individuals at risk of dementia remains difficult because symptoms commonly appear only after significant neurodegeneration. Accessible screening tools that flag subtle cognitive... Read more
AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
Diagnosing the cause of age-related cognitive symptoms remains challenging because clinical presentations of neurodegenerative diseases often overlap, and multiple pathologies can co-occur... Read moreMolecular Diagnostics
view channel
ctDNA MRD Test Identifies Breast Cancer Patients Who May Avoid Surgery
Selecting surgery versus non-surgical management in early-stage breast cancer can be challenging for older patients, who often balance disease control with comorbidities and quality-of-life considerations.... Read more
WGS MCED Assay Demonstrates Rising Sensitivity and High Specificity
Early detection of cancer remains difficult across many tumor types, and current single‑cancer screening modalities leave significant gaps. Blood‑based, multi‑cancer assays aim to detect tumor signals... Read moreHematology
view channel
AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
Bone marrow aspirate examination is central to diagnosing and monitoring blood cancers and other serious hematologic diseases, yet the process in many laboratories remains manual and highly dependent on... Read more
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read moreImmunology
view channel
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read morePathology
view channel
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read more
AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer is typically guided by recurrence risk and population-level averages rather than patient-specific benefit. However, existing clinicopathologic... Read moreIndustry
view channel
Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
Takara Bio USA, Inc. (San Jose, CA, USA), a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company (Reno, NV, USA) announced a development and co-marketing agreement to deliver integrated, automated... Read more







